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Summary Extrapolation to humans from experimental radioimmunotherapy in nude mouse xenograft models is confounded by large relative
tumour size and small volume of distribution in mice allowing tumour uptake of radiolabelled antibodies unattainable in patients. Our large
animal model of human tumours in cyclosporin-immunosuppressed sheep demonstrated tumour uptake of targeted radiolabelled monoclonal
antibodies comparable with uptakes reported in clinical trials. Sheep immunosuppression with daily intravenous cyclosporin augmented by
oral ketoconazole maintained trough blood levels of cyclosporin within the range 1000-1500 ng ml-'. Human tumour cells were transplanted
orthotopically by inoculation of 107 cells: SKMEL melanoma subcutaneously; LS174T and HT29 colon carcinoma into bowel, peritoneum and
liver; and JAM ovarian carcinoma into ovary and peritoneum. Tumour xenografts grew at all sites within 3 weeks of inoculation, preserving
characteristic morphology without evidence of necrosis or host rejection. Lymphatic metastasis was demonstrated in regional nodes draining
xenografts of melanoma and ovarian carcinoma. Colonic LS174T xenografts produced mucin and carcinoembryonic antigen (CEA). The anti-
CEA IgGl monoclonal antibody A5B7 was radiolabelled with iodine-131 and administered intravenously to sheep. Peak uptake at 5 days in
orthotopic human tumour transplants in gut was 0.027% Dl g-' (percentage of injected dose per gram) and 0.034% Dl g-1 in hepatic
metastases with tumour to blood ratios of 2-2.5. Non-specific tumour uptake in melanoma was 0.003% Dl g-1. Uptake of radiolabelled
monoclonal antibody in human tumours in our large animal model is comparable with that observed in patients and may be more realistic than
nude mice xenografts for prediction of clinical efficacy of radioimmunotherapy.
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The nude mouse human tumour xenograft model introduced in
1969 (Rygaard et al, 1969) has facilitated in vivo study of
human cancer and assessment of tumour-targeted therapy under
controlled experimental conditions. However, major limitations
are imposed by allometric and other differences between man and
mouse. There is a 3500-fold difference in weight (20 g vs 70 kg)
and the proportion of mouse body weight constituted by a
xenografted tumour is very high. For a given antibody injected
intravenously, the initial blood concentration is approximately
3500-fold higher in a mouse than in a man (Wahl, 1994). Tumour
blood flow in humans is variable but approximately 0.2 ml of
blood would pass through a 1-g tumour per min, a flow rate at
which it would take 17.4 days for the entire 5-1 blood volume to be
presented to a tumour (Kallinowski et al, 1989). For a 1-g human
tumour xenografted in a mouse the complete circulation time is
only 7.1 min which provides a much greater opportunity for expo-
sure of tumour antigen to systemically administered tumour-
specific monoclonal antibodies.
The small volume of distribution in mice profoundly affects the
plasma half-life and the uptake ofradiolabelled antibody in tumour
measured as percentage of injected dose per gram (% DI g-').
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Uptake of monoclonal antibodies in human tumour xenografts in
nude mice is typically 5-40% DI g-' (Senekowitsch et al, 1989;
Blumenthal et al, 1992; Siler et al, 1993), which contrasts with
much lower uptakes of 0.001-0.01% DI g- of the same radio-
labelled antibody in tumours of the same type in patients (Dykes
et al, 1987; Begent et al, 1990; Yu et al, 1996). This uptake differ-
ential may also be due in part to the murine origin of most mono-
clonal antibodies developed for clinical use, for which the nude
mouse is a syngeneic system. In contrast, effects of cross-reactive
antigens to murine antibodies are observed in the clinical situation
and immunogenicity may also lead to development of human anti-
mouse antibodies (HAMA), which greatly perturbs tumour uptake.
Additional factors that confound reliable clinical extrapolation of
results from experimental radioimmunotherapy of human tumour
xenografts in nude mice include the faster growth rate and higher
susceptibility of tumour to radiation, coupled with the relative
resistance of mice to radiotoxic effects in normal tissue (Knox,
1995). Not only is bone marrow less radiosensitive in the mouse
but because of its small volume it is also relatively spared by the
virtual absence of self absorption of gamma rays and reduced
exposure to high-energy beta emission of therapeutic radio-
nuclides, such as iodine-131 and yttrium-90 (DeNardo et al, 1994).
We have developed a large animal model of human cancer in
immunosuppressed sheep in an attempt to circumvent the prob-
lems of the nude mouse model and avoid the subsequent disap-
pointments ofclinical trials ofradioimmunotherapeutic agents that
had been shown to effectively suppress human tumour xenografts
in rodents (Yu et al, 1996).
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Table 1 Tumour uptake of [3l]A5B7 anti-CEA monoclonal antibody in human LS174T colon cancer xenografts and in normal tissues, in sheep, expressed as
a percentage of dose injected per gram of tissue (% Dl g-1) expressed as the mean (s.d.) of three samples from each animal at 24 h and 3, 5 and 7 days after
i.v. administration, where n = number of animals. Absence of standard deviation indicates that only a single sample was counted
24 Hours (n = 2) 3 Days (n = 2) 5 Days (n = 5) 7 Days (n = 5)
Blood 0.0279 (0.0039) 0.0263 (0.0008) 0.0142 (0.0059) 0.0124 (0.0028)
Liver 0.0091 (0.0014) 0.0066 (0.0001) 0.0051 (0.0032) 0.0040 (0.0018)
Spleen 0.0027 (0.0007) 0.0036 (0.0011) 0.0034 (0.0012)
BM 0.0035 (0.0008) 0.0038 (0.0013) 0.0027
Kidney 0.0059 (0.0008) 0.0054 (0.0018) 0.0050 (0.0014)
Heart 0.0054 (0.0001) 0.0025 (0.0000)
Lung 0.0115 (0.0022) 0.0064 (0.0009)
SK MEL S/C 0.0040 (0.0011) 0.0027 (0.0014) 0.0040 (0.0020)
HT 29 S/C 0.0068 (0.0008) 0.0085 (0.0065) 0.0053 (0.0011)
LS 174T S/C 0.0291 (0.0025) 0.0126 (0.0049) 0.0130 (0.0050) 0.0102 (0.0049)
LS 174T stomach 0.0207 0.0266
LS 174T colon 0.0051 (0.0005)
LS 174T peritoneum 0.0188 0.0208 (0.0052)
LS 174T liver 0.0342 (0.0068) 0.0111 (0.0036)
This study describes the development of a robust and practical
large animal model of human tumours xenografted in cyclosporin-
immunosuppressed sheep. Preliminary results indicate that tumour
uptake of anti-CEA monoclonal antibodies in human colon cancer
xenografts in these sheep is comparable with that reported in clin-
ical trials using the same radiolabelled antibody in patients with
colon carcinoma (Ledermann et al, 1991). These patients were
also treated with cyclosporin, to suppress HAMA response.
In a large animal, in contrast to the mouse, orthotopic transplan-
tation by inoculation of specific tumour cell lines in the organ of
origin of the primary cancer and at sites of predilection for metas-
tasis is relatively easy. Multiple xenografts are available for study
in a single sheep with the additional capacity to carry control
tumours not specific for the radiolabelled monoclonal antibody
under evaluation. This model also allows serial biopsies of
tumours to be taken for time-activity curve analysis in radiation
dosimetry studies, which may be performed in sheep without
sacrificing the animal. Sheep bearing human tumours may also be
imaged on standard gamma camera systems to validate algorithms
for calculation of radiation dosimetry using data obtained from
quantitative single photon emission tomographic imaging in
patients undergoing radioimmunotherapy.
MATERIAL AND METHODS
Animals
Twelve-week-old Merino/dorset-cross sheep weighing approxi-
mately 25 kg (supplied by Murdoch University Animal Farm)
were housed in standard pens each holding six to nine sheep at the
University of Western Australia Animal Facility and allowed to
acclimatize for 10 days. A jugular catheter was inserted under
local anaesthesia and secured for chronic intravenous administra-
tion of cyclosporin over 3-7 weeks. Apart from surgical proce-
dures, no specific sterile precautions were taken and no antibiotics
administered. Food was standard pelleted sheep fodder, supple-
mented with lucerne hay. and was available with water ad libitum.
Immunosuppression was achieved by twice daily intravenous
administration of 3 mg kg-' cyclosporin (kindly donated by
Sandoz Pharma, Basle, Switzerland) via the in-dwelling catheter.
Ketoconazole (Janssen-Cilag Beerse, Belgium) was prepared as an
oral drench formulation (O'Donoghue et al, 1996) and 10 mg kg-'
given twice daily. The sheep were weighed and blood samples
collected every 2 days for cyclosporin assay (EMIT, Syva
Company, Evergreen, CA, USA), and cyclosporin doses were
adjusted to keep the blood trough levels within the range
1000-1500 ng ml-'. Ketoconazole doses were kept constant.
Biochemical and haematological parameters were monitored
before commencement ofcyclosporin and weekly thereafter. When
the CsA levels were stabilized at around 1000 ng ml-', human
tumour cells were injected via different routes ofinoculation, using
halothane anaesthesia for intra-abdominal xenografting. All animal
experimental protocols were approved by the University of
Western Australia Animal Ethics Committee and conformed to the
National Health and Medical Research Council guidelines.
Cell lines and culture
The cell lines used were of human origin. LS174T and HT29,
adenocarcinoma of colon, SK-MEL-5, malignant melanoma and
NIH:OVCAR-3 adenocarcinoma of ovary were all originally
obtained from ATCC. The JAM cell line, a serous cystadenocarci-
noma ofovary (Ward et al, 1987), was kindly provided by Dr Peter
Parsons, Queensland Institute of Medical Research.
The cell lines were maintained in 75-cm2 tissue culture flasks
(Costar, USA) in RPMI 1640 (Life Technologies, USA) supple-
mented with 10% fetal calf serum (FCS) and 100 U ml-' penicillin
(CSL, Australia) and for NIH:OVCAR-3 10% extra FCS and human
insulin (Actrapid, Novo Nordisk, Denmark) at 10 ug ml-' were added
to the media. Confluent cells were harvested using trypsin-versene
(CSL, Australia) counted then washed twice with phosphate-
buffered saline (PBS) to remove FCS and resuspended at a concen-
tration of 108 cells ml-' immediately before injection into sheep.
Cell injections
Injections were given via a 21G needle as 0.1-0.3 ml of cells in
PBS with or without 0.1 ml ofMatrigel (Collaborative Biomedical
Products, USA).
Skin sites
Approximately 107 SK MEL, LS174T, HT 29 and JAM cells in
PBS were injected subcutaneously 5 cm apart on the shaved sides
and flanks of 13 sheep at four injection sites for each cell line.
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Figure 1 (A) Well-formed acinar structures in colon adenocarcinoma arising from subcutaneous injection of LS174T cells H & E stain, 400x. (B) Marked
positive cytoplasmic staining with luminal border accentuation of LS 174T adenocarcinoma with CEA immunoperoxidase stain, 400x. (C) Abundant eosinophilic
intraluminal mucin production by LS 174T adenocarcinoma. PAS stain post diastase, 400x. (D) Whole mount sections of intestinal wall with submucosal tumour
deposit of LS 174T adenocarcinoma of colon. H & E stain. (E) Metastatic tumour deposit of LS 174T adenocarcinoma within the periportal region of the liver. H
& E stain, 10Ox. (F) Macroscopic specimen of lower rectum and anus showing submucosal tumour deposits of LS 174T adenocarcinoma elevating the overlying
intact rectal mucosa
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Intra-abdominal injections
The following procedures were carried out aseptically under
halothane general anaesthetic in the animal operating theatre. At
laparatomy, the cells were injected with or without matrigel using
a 1-ml tuberculin syringe and a 21G needle. Non-absorbing
sutures were placed 2 cm from injection sites for subsequent loca-
tion at laparoscopy or autopsy. The abdominal incision was closed
in layers and the sheep monitored in the recovery room until post-
operative recovery was complete.
Ovarian andperitoneal wallinjections Three sheep received
2 x I07 NIH: OVCAR-3 cells + 0.1 ml of matrigel in one ovary
and two peritoneal wall sites and 2 x 107 JAM cells + 0.1 ml of
matrigel in the opposite ovary and two peritoneal wall sites. Before
closure ofthe peritoneum NIH: OVCAR-3 cells were injected into
the peritoneal cavity of one sheep. In additional sheep, JAM cells
were inoculated into each ovary and at subcutaneous sites.
Colon, liver and peritoneal wall injection Eleven sheep
received 107 LS174T cells in 0.1 ml of matrigel injected into four
sites along the colon or stomach wall and two sites in the liver and
peritoneal wall, as well as one injection each in the liver and
peritoneal wall of 107 LS174T cells without matrigel. In four other
sheep, LS174T cells in matrigel were inoculated at four sites in
rectal submucosa, without laparotomy, by simply prolapsing the
rectum with Allis forceps under halothane anaethesia.
Monitoring tumour growth
Skin tumours were measured weekly in two dimensions with
callipers and the volume calculated using the formula (ab2)/2: a,
representing the longest dimension and b, the shortest. Volumes
are stated as mean ± s.d., with n = number of tumours measured.
Tumours were excised from the skin at varying times and fixed in
formalin for subsequent histological examination. At autopsy, 3-6
weeks after tumour cell inoculation appropriate organs and
draining lymph nodes were removed, examined macroscopically
and fixed in formalin for histology. Portions of unfixed draining
lymph nodes were collected in tissue culture medium, minced with
scissors and pushed through a cell dissociation sieve (Sigma
USA). The resultant cell suspension was washed twice and seeded
into cell culture flasks with RPMI 1640 plus 20% FCS for growth
ofadherent cells.
Histology and immunocytochemistry
Tissues for histopathological examination were fixed in neutral-
buffered formalin and processed in the routine fashion through
alcohol and xylene to paraffin. Sections were cut at 4 microns and
stained with Harris haematoxylin and aqueous eosin (H and E
stain).
Mucins in tissues were demonstrated using the periodic acid-
Schiff reaction (PAS). Mucins were oxidized by periodate to
expose aldehydes, which were demonstrated with Schiffs reagent.
Any glycogen in the tissue was removed by prior treatment with
fresh malt diastase. The neutral mucin appeared as bright
eosinophilic amorphous material.
Carcinoembyronic antigen (CEA) was demonstrated using
rabbit anti-human CEA (Dakopatts, Glostrup, Denmark) on
formalin-fixed, paraffin-embedded tissue. Antigen demonstration
was achieved by a peroxidase-conjugated streptavidin staining
procedure. The primary antibody was first applied to the tissue
sections, which were then further labelled with a biotinylated link
antibody followed by a streptavidin peroxidase enzyme conjugate.
The bound peroxidase enzyme was then visualized with a
diaminobenzidine substrate.
Antibody: labelling, injection and biodistribution
A5B7 anti-CEA IgGI monoclonal antibody kindly donated by
Celltech, UK, was labelled with 1-131 using the Chloramine-T
method (Pedley et al, 1987). Labelling efficiency was 98% without
loss ofimmunoreactivity.
For each sheep, 0.1 mg ofA5B7 antibody was labelled with 15-
MBq'3'I and 0.1 mg kg-' cold A5B7 antibody was added immedi-
ately before intravenous administration for tissue distribution
studies. For tumour imaging, 185-MBq 3'I was used with the same
proportion ofA5B7 antibodies.
Sheep were euthanased using a lethal injection ofsodium pento-
barbitone at 1, 3, 5 or 7 days after administration of radiolabelled
antibody. The human tumour xenografts were removed and
weighed, and samples of blood, liver, spleen, kidney, thyroid,
heart, lung, lymph node, bone marrow and bile samples were
weighed and counted for 10 min in a gamma counter (Wallac 1480
Wizard, Wallac Oy, Turku, Finland). The % DI g-' was calculated
for each sample taken.
Sheep, under halothane anaesthesia, were imaged at 3, 5 or 7
days after intravenous ['311]-ASB7-radiolabelled monoclonal anti-
CEA antibody, using an Elscint Apex 409 gamma camera and
high-energy collimator. After lethal injection of pentobarbitone, a
flap of tumour-bearing skin was excised and pinned out on foam
board and imaged for 20 min. Cobalt-57 markers were then placed
on the tumours and scanned to mark the exact location of each
tumour on the scintigraphic images.
RESULTS
Human LS174T and HT 29 adenocarcinoma of colon
Subcutaneous flank inoculation of LS174T and HT 29 cells gave
rise to tumours that grew steadily up to day 21 but then apparently
stabilized at a mean tumour volume of 1805 ± 1184 mm3 (n = 20)
for LS174T and 931 ± 991 mm3 (n = 20) for HT29.
Neither of the colonic adenocarcinomas metastasized to
regional lymph nodes after subcutaneous inoculation, and serum
CEA levels did not rise.
On histological examination the tumour deposits of LS174T
exhibited the features of a well-differentiated adenocarcinoma
with prominent well-formed acinar formations throughout the
tumour, lined by columnar cells with mild to moderate nuclear
pleomorphism (Figure lA). Atypical mitotic figures were present
but not numerous. There was marked cytoplasmic positivity with
luminal accentuation with the immunoperoxidase preparation for
CEA (Figure IB). The LS174T tumour produced abundant neutral
mucin, showing marked positivity with the PAS preparation post
diastase (Figure lC).
The less well-differentiated HT29 adenocarcinoma, in contrast
to the LS174T tumour deposits, showed little tendency toward
acinar formation, with moderate to marked nuclear pleomorphism,
including tumour giant cells. Cytoplasmic vacuolization was
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Figure 2 (A) Subcutaneous SK MEL melanoma in diffuse sheets
with no necrosis ortumour-infiltrating lymphocytes. H & E stain,
400x. (B) Whole mount section of a regional lymph node showing
extensive deposits of metastatic SK MEL melanoma. H & E stain.
(C) Macroscopic specimen of JAM ovarian carcinoma diffusely
infiltrating both ovaries with metastatic spread into paratubal
mesentry. (D) Paratubal lymphatic vascular permeation from
ovarian tumour deposit of JAM ovarian adenocarcinoma. H & E
stain, 250x. (E) JAM ovarian adenocarcinoma forming poorly
differentiated glands adjacent to an ovarian follicle (top). H & E
stain, 400x.
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Figure 3 Excised skin flap from sheep flank (left panel), reversed to show human tumour xenografts of HT 29 (top) and LS 174T (second row), SK MEL (third
row) and LS 174T tumours implanted directly from nude mice (bottom). Administration of iodine-131 -radiolabelled A5B7 anti-CEA monoclonal antibody 72 h
before ex vivo gamma imaging demonstrated discrete uptake in LS 174T tumours with minimal activity in HT 29 tumour and no activity in SK MEL melanoma
xenografts (middle panel). Matching of tumour uptake of activity on the gamma camera images was performed by imaging of cobalt-57 markers shown in situ in
the corresponding positions (right panel)
apparent, including occasional intracytoplasmic pseudolumina and
numerous atypical mitoses were present. Only a small amount of
neutral mucin was demonstrated in HT29 tumours, present as scat-
tered intracytoplasmic mucinous globules. The immunoperoxidase
preparation for CEA decorated the tumour cells in a variably weak
focally accentuated cytoplasmic pattern.
Intra-abdominal tumour deposits of LS174T in peritoneum and
intestinal wall (Figure 1D) displayed the characteristic histological
features described above. Although some peritumoral fibrosis was
present, no necrosis or tumour-infiltrating lymphocytes were seen.
Metastatic LS174T tumours measuring 2 mm in diameter in liver
were centred on portal tracts, suggesting tumour seeding via the
portal vein (Figure 1E). The tumours were evident macroscopi-
cally, for example in lower rectum (Figure IF).
Human SK-MEL melanoma
Tumours grew steadily at sites of subcutaneous inoculation and
attained a mean volume of 3443 ± 2734 mm3 (n = 20) within 37
days of inoculation of 107 cells in five sheep. At this time, SK-
MEL cells were recovered from the pre-stifle lymph node that
drains the flank bearing the subcutaneous melanoma xenografts.
Cells grown in culture from these regional lymph nodes then gave
rise to SK-MEL tumours when subsequently reinoculated into
other immunosuppressed sheep. The growth curve of reinoculated
cells shifted slightly to the left, but the histological appearance
remained consistent.
Tumour deposits of SK-MEL were present in diffuse sheets of
large pleomorphic polygonal and cuboidal cells with abundant
amphophilic cytoplasm, enlarged vesicular nuclei and prominent
eosinophilic nucleoli. Atypical mitoses were easily identified. No
significant necrosis was evident, and there was only a variable
mild inflammatory host response with infrequent tumour-infil-
trating lymphocytes (Figure 2A). The tumour cells showed
markedly positive staining with S100 protein.
Spontaneous metastasis to draining regional lymph nodes was
observed (Figure 2B), and the metastatic nodal deposits showed
similar architectural and cytological features to those of the
primary tumour deposit (Figure 2A).
Human JAM and NIH:OVCAR-3 cystadenocarcinoma of
ovary
JAM cells inoculated subcutaneously in the flank gave rise to
tumours attaining a mean volume 653 ± 376 mm' by day 28. Ifco-
injected with Matrigel, subcutaneous JAM cell tumours attained a
volume of 1026 ± 1043 mm3 within the same period. Tumour cell
spread to regional lymph nodes from subcutaneous inoculation
sites ofJAM cells was demonstrated by histology and recovery of
JAM cells by tissue culture ofthe minced pre-stifle lymph nodes.
Subcutaneous inoculation of NIH:OVCAR-3 cells did not give
rise to tumours in the 28-day period ofobservation.
Inoculation of JAM cells in Matrigel directly into the ovary
gave rise to tumours within 21 days in all animals.
Bilateral ovarian tumour deposits and extensive paratubal
masses (Figure 2C) were typical at 1 month after direct ovarian
inoculation of JAM cells. Histopathological examination
confirmed paratubal lymphatic permeation (Figure 2D). There
were predominantly diffuse sheet-like arrangements of pleo-
morphic malignant cells showing variable cytological features.
Tumour giant cells were prominent with moderate to marked
nuclear pleomorphism, and atypical mitoses were easily identified
(Figure 2E). No definite papillary structures were present.
Subperitoneal inoculation of JAM cells in Matrigel was also
productive of tumours at all sites with similar histological
appearance.
Administration ofNIH:OVCAR-3 tumour cells directly into the
peritoneal cavity resulted in bladder tumour deposits exhibiting a
predominantly diffuse architecture with occasional slit-like
spaces. The neoplastic cells exhibited variable cytological features
with cuboidal and spindeloid cells admixed with markedly pleo-
morphic and occasionally multinucleated cells. Marked nuclear
pleomorphism was evident and atypical mitoses easily identified.
A mild chronic inflammatory host response was present, but there
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was no tumour necrosis and only small numbers of tumour-infil-
trating lymphocytes were evident focally, confined to the
periphery of the tumour deposits.
Imaging and uptake
Subcutaneous LS 174T and HT29 tumour xenografts could not be
defined in vivo by gamma camera imaging because of relatively
high blood background activity. However, ex vivo imaging of the
tumour-bearing skin flap did demonstrate foci of tumour-specific
uptake in LS 174T, and to a lesser extent in xenografts of HT29
(Figure 3). There was no visible activity in the control SK MEL
tumours. The mean uptake of ['311]A5B7 in LS174T colon cancer
xenografts and normal tissues in the immunosuppressed sheep
(Table 1) demonstrated highest tumour to blood ratios of 2-
2.5 at 5 days post injection of antibody when mean uptakes of
0.034% DI g-' in liver metastases and 0.027% DI g-' in intestinal
LS174T xenografts were achieved. At each time point, uptake of
[1311]A5B7 was highest in LS174T xenografts, next highest in
HT29 tumours, which was greater than normal liver activity and
uptake was least in SK-MEL tumours.
DISCUSSION
The great expectations of radioimmunotherapy of cancer meta-
stasis raised by encouraging results in human tumour xenografts
treated in nude mice have yet to be realized in patients (Sgouros,
1995).
Extrapolation from nude mouse xenograft tumour models to
humans is primarily limited by the relatively small size and
volume of distribution in mice that promotes uptake of systemi-
cally administered antibody in transplanted human tumour to
levels unattainable in patients (Knox, 1995). There are also signif-
icant differences between humans and mice in self-absorption of
radiation, bone marrow radiosensitivity and repopulation kinetics,
tumour cell cycle time and volume-doubling time and the presence
of cross-reactive antigens (Wahl, 1994). To avoid these problems,
we have developed a large animal model of human tumours in
immunosuppressed sheep. We have previously shown that
cyclosporin effectively abrogates immunocompetence in sheep
and that this immunosuppressive effect is enhanced by concomi-
tant administration ofketoconazole (O'Donoghue et al, 1996),just
as is observed in man (Schroeder et al, 1987). We have also shown
that daily combined therapy comprising intravenous cyclosporin
via in-dwelling jugular vein catheter and oral ketoconazole given
in a drench formulation to bypass the rumen and facilitate
abomasal absorption will effectively suppress the immune
response for several weeks. Biochemical monitoring of these
animals showed no evidence of nephrotoxicity or hepatotoxicity if
trough blood levels of cyclosporin remained below 1500 ng ml,
above which the sheep became anorexic and lost condition. The
apparent tolerance of sheep to maintenance ofcyclosporin at these
relatively high blood levels contrasts with the renal transplant
experience in humans, in whom trough levels of 500 ng ml-'
immediately after kidney grafting have to be reduced to mainte-
nance levels of typically 100-200 ng ml to avoid cyclosporin-
induced nephrotoxicity.
We have previously observed that our chronically immuno-
suppressed sheep tolerate full-thickness heterologous skin grafts
without histological evidence of rejection, provided that trough
blood cyclosporin levels are maintained above 750 ng ml'. At the
optimum serum level of 1000 ng ml', the sheep remained healthy
with no apparent increase in susceptibility to infection. They had
no requirement for prophylatic antibiotics, sterile feed or aseptic
environment. Sheep were penned together and aseptic conditions
prevailed only during surgical procedures. Thus, the cyclosporin-
immunosuppressed sheep offers a practical and relatively robust
model that can be used to study human tumours in an animal of
comparable size.
Adequacy of immunosuppression of the sheep was reflected in
the minimal histological features of regression in all the human
tumour transplants examined. Most tumour deposits showed a
mild lymphocyte inflammatory host response without significant
necrosis and no tumour-infiltrating lymphocytes. Some deposits
were surrounded by a marked chronic inflammatory host response
with or without a desmoplastic mesenchymal proliferation, and
this tended to occur in exposed sites of inoculation, such as skin
and gastrointestinal submucosal deposits, perhaps in response to
an additional antigenic stimulation.
Subcutaneous inoculation ofhuman tumour cells in the flanks of
sheep may be performed easily at multiple sites without anaes-
thesia. Given optimum cyclosporin levels, virtually all inoculates
of 107 cells of LS174T and HT29 human colon carcinoma and
SKMEL human melanoma and JAM human ovarian carcinoma
grew to a size of 1-2 cm over a period of 3 weeks. In general, the
individual tumour cell morphology in our animals remained
unchanged but some tumour deposits showed a variable degree of
dedifferentiation. For instance, LS174T deposits often exhibited
focal areas of the classical well-differentiated large acinar forma-
tions merging with poorly differentiated areas, and some deposits
were entirely poorly differentiated. The practical significance of
these findings, particularly in reference to CEA expression, poten-
tial for aggressive tumour behaviour and tumour uptake of anti-
CEA monoclonal antibody have yet to be determined in this
animal model. Histological examination did, however, demon-
strate maintenance of the comparative dedifferentiation of HT29
tumour cells in comparison with LS174T, in which the well
defined acinar structures were shown to produce more mucin and
had greater CEA expression on immunoperoxidase staining. These
differences were reflected in the relatively greater tumour uptake
ofanti-CEA monoclonal antibody in LS174T than in HT29 human
colon cancer xenografts. Weekly monitoring of serum CEA levels
in sheep bearing colon cancer xenografts did not show any eleva-
tion, which accords with data from LS174T xenografts in nude
mice (Pedley et al, 1987). The SKMEL tumours showed typical
morphological characteristics of human melanoma and did not
accumulate radiolabelled anti-CEA antibody.
Evidence of some loss of differentiation was observed in both
colon and ovarian carcinomas. Dedifferentiation was focal in
the LS174T tumour deposits but was evident throughout the
xenografts of JAM and NIH: OVCAR-3 ovarian serous adeno-
carcinoma, in which the expected papillary formations were not
observed. It is possible that this relative tumour dedifferentiation
may have been the result of multiple passaging of cell lines, but
further study is required to exclude various host factors.
The melanoma was observed to metastasize from subcutaneous
sites of inoculation, and SKMEL cells were subsequently recov-
ered from the regional pre-stifle lymph node, grown in cell culture
and reinoculated subcutaneously in sheep, giving rise to tumours
morphologically indistinguishable from those of the primary
inoculation. JAM ovarian carcinoma also metastasized to regional
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lymph nodes draining both subcutaneous and ovarian sites of inoc-
ulation. The failure of tumours to metastasize from subcutaneous
sites in nude mice models is well documented (Fidler, 1990;
Kubota, 1994), and Manzotti et al (1993) have reviewed the
importance of orthotopic transplantation of human tumours in
relation to metastasis and invasion.
Orthotopic transplantation of LS174T human colon cancer in
the sheep was achieved by inoculation of 107 cells into the wall of
stomach and colon, and hepatic metastases were induced by intra-
venous administration by portal vein or simulated by intrahepatic
inoculation. Direct subperitoneal implantation was also successful.
Spontaneous metastasis to liver or lymph nodes was not observed
in these animals possibly because of the relatively short duration
oftheexperiment (3 weeks) and not having a reliable technique, as
yet, for locating small numbers of tumour cells deposited within
the liver and lymph nodes. Studies of metastasis may be facilitated
by orthotopic implantation of intact human tumours (Fu et al,
1991), which would be relatively easy in sheep in comparison with
mice and may be performed at multiple sites in the same animal. In
later experiments, we achieved orthotopic xenografts of LS174T
colonic carcinoma without laparatomy, simply by inoculating 107
cells in Matrigel submucosally in the partly everted rectum, under
halothane anaesthesia. Monitoring of these tumours by digital
rectal examination was simple and serial biopsy can be performed
under direct vision via proctoscopy. This location more accurately
reflects the location of the tumours in humans compared with
stomach and small intestine and, with further experiments of
longer duration, may give rise to metastasis.
Matrigel, a reconstituted basement membrane matrix (Fridman
et al, 1991), was found to facilitate tumour take at sites of cell
inoculation particularly for NIH: OVCAR-3 and JAM human
ovarian carcinoma cells orthotopically transplanted into sheep
ovaries. Enhancement of tumour growth was also observed after
transplantation of multicell spheroids of LS 174T cells in compar-
ison with inoculation of LS 174T single-cell suspension at the
same sites. We also found that LS174T xenografts grown subcuta-
neously in nude mice from cell inoculations, when implanted into
the immunosuppressed sheep subdermally grew more rapidly than
xenografts arising from inoculation of LS174T single-cell suspen-
sions. The uptake of ['311]A5B7 anti-CEA monoclonal antibody
was similar for such implanted tumour chunks to that observed in
subcutaneous LS174T xenografts originating from inoculation of
cell suspensions, and both were demonstrated on ex-vivo gamma
camera images taken 3-5 days after administration of the radio-
labelled anti-CEA antibody (Figure 3).
The tumour uptake in LS 174T xenografts shown in Table 1 is in
accord with that achieved in human colonic tumour studies in
patients using ['3'I]A5B7 anti-CEA monoclonal antibody, when
peak uptake of 0.018% DI g-' was observed at 27 h after adminis-
tration of radiolabelled intact antibody (Lane et al, 1994). These
modest tumour uptakes in sheep contrast with those achieved in
LS174T human colon cancer xenografts in nude mice in which
[1'3I]A5B7 peak tumour uptake is over 20% DI g-I (Pedley et al,
1993). Not only is tumour uptake of antibody much higher in
LS174T xenografts in nude mice, but comparison of the distribu-
tion of the same radiolabelled antibody in a mouse model and in
patients has shown different distribution in tumour and normal
tissues (Begent et al, 1990). In contrast, we have shown that the
distribution of ['311I]A5B7 anti-CEA monoclonal antibody between
human LS 174T colon cancer xenografts in sheep and normal ovine
tissues (Table I) is comparable with that reported in patients
with colon carcinoma using '31l-anti-CEA-radiolabelled antibody
(Begent et al, 1989), although blood clearance was slower.
Relatively high human tumour uptakes of radiolabelled anti-
bodies are commonly achieved in nude mouse xenografts
(Senekowitsch et al, 1989; Siler et al, 1993), but the typical uptakes
for the same antibody and tumour type in man are around 0.005%
DI g-' (Dykes et al, 1987; Begent et al, 1990). Expectations of
curability of tumours by radioimmunotherapy based on nude
mouse results are therefore unrealistic. For example, if a 60-Gy
dose in 1 week is considered sufficient for tumour sterilization, and
given a tumour uptake of '3ll-labelled monoclonal antibody of
0.005% DI g-', the corresponding whole-body radiation absorbed
dose would be 17 Gy (Vaughan et al, 1986). The maximum toler-
able whole-body dose in man is in fact around 2 Gy and new
approaches to radioimmunotherapy of solid tumours will be neces-
sary. One such approach is regional therapy, and the comparable
size and anatomy ofthe sheep will facilitate exploration of methods
of local and intratumoral radioimmunotherapy. For example, we
have inoculated our immunosuppressed sheep with human tumour
cells in liver and in peritoneum to provide models for regional
radioimmunotherapy delivered via hepatic artery or intra-peritoneal
injection. Monitoring by quantitative gamma camera imaging is
easily performed in this large animal model. In addition, results can
be correlated with counting of serial biopsy samples and auto-
radiography to validate algorithms for calculation of dosimetry in
patients in subsequent clinical trials to evaluate safety and efficacy
of radioimmunotherapy of cancer.
Modelling of micrometastasis in the immunosuppressed sheep
may be contemplated, for instance, by surgical removal of the
'primary' site of ovarian xenografting of JAM cell tumour after
metastasis has occurred. Subsequent treatment with intraperitoneal
radiolabelled monoclonal antibodies and second-look surgery may
allow more complete evaluation of the efficacy of adjuvant
radioimmunotherapy than can be performed in clinical trials.
Other modalities ofadjuvant therapy may conceivably be tested in
the sheep model. For example, the efficacy and toxicity of
external-beam radiotherapy for adjuvant treatment of rectal
carcinoma may potentially be assessed in ovine rectal tumour
xenografts ofhuman LS174T colon cancer.
We have demonstrated that a variety of human cancers may be
orthotopically xenografted in immunosuppressed sheep. This large
animal model has the potential for preclinical evaluation of novel
treatments of human tumours under controlled experimental
conditions that approach the human condition much more closely
than those prevailing in a nude mouse. Assessment of adjuvant
treatments, such as radioimmunotherapy, of human tumour
xenografts in immunosuppressed sheep may thus improve predic-
tion oftheir therapeutic efficacy in patients.
ACKNOWLEDGEMENTS
We wish to thank Andrew Martindale and Magda Carcione for
nuclear medicine technology assistance, Denham Heliams and
Megan Carter for animal welfare, Linda Manning and Helen
O'Donoghue for performing preliminary experimental studies and
Ken Ilett for pharmacological advice and provision ofcyclosporin
assays. We also gratefully acknowledge Paul Norman, Cameron
Platell and Andrew Barker who performed intra-abdominal
surgery, Len Maker and Peter Hall who prepared the pathology
specimens and photographs, Greg Sheridan for haematology and
Jenny Lavin for processing the manuscript.
@ Cancer Research Campaign 1998 British Joumal ofCancer(1998) 78(4), 486-494494 JH Turner etal
The cyclosporin was kindly donated by Sandoz Pharma (Basle)
(now Novartis), and the encouragement and support of Jurg
Schaedlin and William Harrison is acknowledged with thanks.
Celltech (Slough, UK) generously donated A5B7 antibody, and the
expert advice from David King in respect of radiolabelling was
much appreciated. Degussa Australia, for donating Ultrasil VN3
for the drench formulation, subsidy of ketoconazole by Janssen-
Cilag and ofEMIT assays by Syva Co are also gratefully acknowl-
edged. The study was funded by a National Health and Medical
Research Council Project Grant.
REFERENCES
Begent RHJ and Pedley RB (1990) Antibody targeted therapy in cancer: comparison
of murine and clinical studies. Cancer Treat Rev 17: 373-378
Begent RHJ, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, Keep PA,
Adam T, Dale RG and Glaser MG (1989) Antibody distribution and dosimetry
in patients receiving radiolabelled antibody therapy for colorectal cancer. BrJ
Cancer 60: 406-412
Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA,
Kennel SJ and Goldenberg DM (1992) Targeted therapy ofathymic mice
bearing GW39 human colonic cancer micrometastases with '3l1-labelled
monoclonal antibodies. Cancer Res 52: 6036-6044
DeNardo GL, Kroger LA, DeNardo SJ, Miers LA, Salako Q, Kukis DL, Fand I,
Shen S, Renn 0 and Meares CF (1994) Comparative toxicity studies of
Yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-
3). Cancer 73 (suppl.): 1012-1022
Dykes PW, Bradwell AR, Chapman CE and Vaughan ATM (1987)
Radioimmunotherapy ofcancer: clinical studies and limiting factors. Cancer
Treat Rev, 14: 87-106
Fidler I (1990) Critical factors in the biology ofhuman cancer metastasis: Twenty-
eighth G.H.A. Clowes Memorial Award Lecture. CancerRes 50: 6130-6138
Fridman R, Kibbey MC, Royce LS, Thomas MZ, Sweeney M, Jicha DL, Yanelli JR,
Martin GR and Kleinman HK (1991) Enhanced tumour growth of both primary
and established human and murine tumour cells in athymic mice after
coinjection with matrigel. JNatl Cancer Inst 83: 769-774
Fu X, Besterman JM, Monosov A and Hoffman RM (1991) Models ofhuman
metastatic colon cancer in nude mice orthotopically constructed by using
histologically intact patient specimens. Proc NatlAcad Sci USA 88: 9345-9349
Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P and
Vaupel P (1989) Blood flow metabolism, cellular microenvironment and
growth rate ofhuman tumour xenografts. CancerRes 49: 3759-3764
Knox SJ (1995) Overview of studies on experimental radioimmunotherapy. Cancer
Res 55 (suppl.): 5832-5836
Kubota T (1994) Metastatic models ofhuman cancer xenografted in the nude mouse:
the importance oforthotopic transplantation. J Cell Biochem 56: 4-8
Lane DM, Eagle KF, Begent RHJ, Hope-Stone LD, Green AJ, Casey JL, Keep PA,
Kelly AMB, Glaser MG and Hilson AJW (1994) Radioimmunotherapy of
metastatic colorectal tumours with iodine-131-labelled antibody to
carcinoembryonic antigen: phase 1/11 study with comparative biodistribution of
intact and F(ab'), antibodies. BrJ Cancer 70: 521-525
Ledermann JA, Begent RHJ, Massof C, Kelly AMB, Adam T and Bagshawe KD
(1991) A phase-1 study ofrepeated therapy with radiolabelled antibody to
carcinoembryonic antigen using intermittent or continuous administration of
cyclosporin A to suppress the immune response. Int J Cancer 47: 659-664
Manzotti C, Riccardo A and Pratesi G (1993) Importance oforthotopic implantation
for human tumors as model systems: relevance to metastasis and invasion. Clin
Exp Metastasis 11: 5-14
O'Donoghue HL, Penhale WJ, Manning LS, Reynoldson JA and Tumer JH (1996)
Cyclosporine A immunosuppression in sheep with response enhancement by
concomitant ketoconazole. Clin Exp Pharmacol Physiol 23: 797-803
Pedley RB, Boden J, Keep PA, Harwood PJ, Green AJ and Rogers GT (1987)
Relationship between tumour size and uptake ofradiolabelled anti-CEA in a
colon tumour xenograft. EurJ Nucl Med 13: 197-202
Pedley RB, Boden JA, Boden R, Dale R and Begent RHJ (1993) Comparative
radioimmunotherapy using intact ofF(ab'), fragments of '3'I anti-CEA antibody
in a colonic xenograft model. BrJ Cancer 68: 69-73
Rygaard J and Povlsen CO (1969) Heterotransplantation ofa human malignant
tumour to nude mice. Acta Pathol Microbiol Scand 77: 758-760
Schroeder TJ, Melvin DB, Clardy CW, Wadhwa NK, Myre SA, Reising JM, Wolf
RK, Collins JA, Pesce AJ and First MR (1987) Use ofcyclosporine and
ketoconazole without nephrotoxicity in two heart transplant recipients. JHeart
Transplant 6: 84-89
Senekowitsch R, Reidel G, Mollenstadt S, Kriegal H and Pabst HW (1989) Curative
radioimmunotherapy ofhuman mammary carcinoma xenografts with Iodine
131-labeled monoclonal antibodies. JNucl Med30: 531-537
Sgouros G (1995) Radioimmunotherapy ofmicrometastases: side-stepping the solid-
tumour hurdle. JNucl Med36: 1910-1912
Siler K, Eggensperger D, Hand PH, Milenic DE, Miller LS, Houchens DP, Hinkle G
and Schlom J (1993) Therapeutic efficacy ofa high-affinity
anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotech Ther 4:
163-181
Vaughan ATM, Bradwell AR, Dykes PW and Anderson P (I1986) Illusions oftumour
killing using radiolabeled antibodies. Lancet 1: 1492-1493
Wahl RL (1994) Experimental radioimmunotherapy. Cancer 73 (suppl.): 989-992
Ward BG, Wallace K, Shepherd JH and Balkwill FR (1987) Intraperitoneal
xenografts ofhuman epithelial ovarian cancer in nude mice. CancerRes 47:
2662-2667
Yu B, Carrasquillo J, Milenic D, Chung Y, Perentesis P, Feuerestein 1, Eggensperger
D, Qi C-F, Paik C, Reynold J, Grem J, Curt G, Siler K, Schlom J and Allegra C
(1996) Phase I trial of Iodine 131-labeled COL-1 in patients with
gastrointestinal malignancies: influence of serum carcinoembryonic antigen
and tumour bulk on pharmacokinetics. J Clin Oncol 14: 1798-1809
British Journal ofCancer (1998) 78(4), 486-494 c3 CancerResearch Campaign 1998